Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
This study will evaluate the combination of a fixed dose pembrolizumab/vibostolimab co-formulation (MK-7684A) with etoposide/platinum chemotherapy followed by MK-7684A compared to the combination of atezolizumab with etoposide/platinum chemotherapy followed by atezolizumab in the first-line treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC). The primary hypothesis is, with respect to overall survival, MK-7684A in combination with the background therapy of etoposide/platinum followed by MK-7684A, is superior to atezolizumab in combination with the background therapy of etoposide/platinum followed by atezolizumab.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
Plus 4 other study approaches.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Jul 8, 2025 · Source: ClinicalTrials.gov
The study is underway but is not accepting new participants.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 3
- Sponsor
- Merck Sharp & Dohme LLC
- Interventions being studied
- Biological: Pembrolizumab/Vibostolimab Co-Formulation; Drug: Saline placebo; Drug: Etoposide; Drug: Cisplatin; Biological: Atezolizumab; Drug: Carboplatin
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- The main inclusion criteria include but are not limited to the following:
- Has histologically or cytologically confirmed diagnosis of extensive-stage small cell lung cancer (ES-SCLC) in need of first-line therapy
- Has ES-SCLC defined as Stage IV (T any, N any, M1a/b/c) by the American Joint Committee on Cancer, Eighth Edition or T3-T4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan
- Males agree to use contraception, refrain from donating sperm, and abstain from heterosexual intercourse
- Females are not pregnant or breastfeeding, is not a woman of childbearing potential (WOCBP) or is a WOCBP who uses a highly effective contraceptive method, or is abstinent from heterosexual intercourse
- Has measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
- Has a predicted life expectancy of \>3 months
The main
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Infirmary Cancer Care ( Site 0022)Mobile, Alabama
- Los Angeles Hematology Oncology Medical Group ( Site 0006)Los Angeles, California
- VA West Los Angeles Medical Center ( Site 0004)Los Angeles, California
- Boca Raton Regional Hospital-Lynn Cancer Institute ( Site 0014)Boca Raton, Florida
- Fort Wayne Medical Oncology and Hematology ( Site 0013)Fort Wayne, Indiana
- Dana-Farber Cancer Institute ( Site 0018)Boston, Massachusetts
- Cancer and Hematology Centers of Western Michigan ( Site 0001)Grand Rapids, Michigan
- Hattiesburg Clinic Hematology/Oncology ( Site 0003)Hattiesburg, Mississippi
- Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0005)Lancaster, Pennsylvania
- Blue Ridge Cancer Care ( Site 0015)Blacksburg, Virginia
- University of Virginia Cancer Center ( Site 0019)Charlottesville, Virginia
- Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 0203)Ciudad Autonoma de Buenos Aires, Buenos Aires
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 8, 2025. Always confirm current availability with the study team.